5-Hydroxytryptophan (5-HTP) is the direct metabolic precursor to serotonin (5-hydroxytryptamine, 5-HT). In the normal serotonin synthesis pathway, dietary tryptophan is first converted to 5-HTP by tryptophan hydroxylase (TH) — a rate-limited, tightly regulated enzyme — and then to serotonin by aromatic amino acid decarboxylase (AAAD). 5-HTP bypasses the TH bottleneck entirely: it is taken up directly by serotonergic neurons and converted to serotonin within minutes by AAAD, which is not rate-limited.
This makes 5-HTP pharmacologically distinct from L-tryptophan supplements: tryptophan must first compete with other large neutral amino acids for blood-brain barrier transport, then be converted by the regulated TH enzyme. 5-HTP crosses the blood-brain barrier directly via the large neutral amino acid (LNAA) transporter with approximately 70% efficiency — most of an oral dose reaches the brain. This efficiency is what makes 5-HTP clinically meaningful and also what makes it genuinely risky in combination with serotonergic drugs.
The most studied application. A series of European RCTs conducted in the 1990s (primarily Italian and Swiss researchers) compared 5-HTP 300mg/day to fluvoxamine (an SSRI) and found comparable reductions in Hamilton Depression Rating Scale (HAMD) scores over 6 weeks, with 5-HTP showing somewhat better tolerability. A 2002 Cochrane review found 5-HTP superior to placebo in two adequately controlled trials. A 2021 Nutrients systematic review of 11 RCTs (including combination with carbidopa to prevent peripheral conversion) found 5-HTP consistently outperformed placebo for depression outcomes.
The evidence is consistent but most trials are small (30–100 patients), short (6–12 weeks), and old. Large, modern, independently funded RCTs are lacking. For mild-to-moderate depression, 5-HTP has meaningful evidence — but for clinical depression, it should not replace evidence-based treatments without physician guidance.
Serotonin is the precursor to melatonin in the pineal gland: serotonin → N-acetylserotonin → melatonin, via SNAT and ASMT enzymes, stimulated by darkness. Increasing serotonin availability (via 5-HTP) can increase melatonin production if taken in the evening. A 2010 study in Nutritional Neuroscience found a combination of 5-HTP and GABA reduced sleep onset time and increased sleep duration vs. placebo. The effect on sleep is real but mediated by melatonin — taking 5-HTP 60–90 minutes before bed, in a dark or dim-light environment, is more effective than afternoon dosing.
Serotonin plays a significant role in satiety signaling, particularly for carbohydrate intake. Two RCTs from Cangiano et al. (1991, 1992) studied 5-HTP 900mg/day in obese non-diabetic and type 2 diabetic patients, respectively, and found significant reductions in carbohydrate intake, total caloric intake, and body weight compared to placebo over 12 weeks — without explicit dietary restriction instructions. The mechanism is serotonin-mediated early satiety signaling. This is the same reason SSRIs cause initial weight loss in some patients and also why carb cravings spike when serotonin is low. The dose required (750–900mg/day) is higher than typical mood/sleep doses.
| Use Case | Dose | Timing | Notes |
|---|---|---|---|
| Mood support / mild depression | 100–300mg/day | Split: morning + evening with meals | Start at 50–100mg; titrate up over 2 weeks. Takes 2–4 weeks for full effect. |
| Sleep onset / quality | 100–200mg | 60–90 min before bed, in dim light | Pairs well with GABA or magnesium glycinate for synergistic effect |
| Appetite and carb craving reduction | 250–300mg, 3× daily | 30 min before meals | This is the Cangiano et al. RCT protocol; highest effective dose range |
| Fibromyalgia / chronic pain | 100mg 3× daily (300mg/day) | With meals | Small positive RCT exists; takes 4–6 weeks |
5-HTP must NOT be combined with any serotonergic medication without physician supervision. This includes SSRIs (fluoxetine, sertraline, escitalopram, paroxetine), SNRIs (venlafaxine, duloxetine), MAOIs (phenelzine, tranylcypromine), tramadol, triptans (sumatriptan), lithium, and St. John's Wort. The combination can produce serotonin syndrome — a potentially life-threatening condition characterized by agitation, confusion, rapid heart rate, high blood pressure, muscle rigidity, hyperthermia, and in severe cases, seizures and death. This is not a theoretical risk; multiple case reports exist. If you are on any of these medications, do not self-supplement with 5-HTP.
Long-term use caution: Animal studies suggest long-term high-dose 5-HTP may downregulate dopamine production over time (serotonin and dopamine share synthesis pathways and compete for AAAD enzyme activity). Some practitioners recommend pairing 5-HTP with L-DOPA precursors (L-tyrosine or L-DOPA, via mucuna pruriens) for long-term use, though human evidence for this protocol is limited.
EMS history note: In 1989, a contaminated batch of L-tryptophan caused eosinophilia-myalgia syndrome (EMS), killing 37 people. 5-HTP uses a different, plant-based production process (Griffonia simplicifolia seed) and a different manufacturing pathway — no EMS cases have been attributed to 5-HTP in decades of use. The historical warning is sometimes applied to 5-HTP incorrectly.
5-HTP 100mg Supplement → Magnesium Glycinate →As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.